A novel antibiotic produced by Streptomyces noursei Da07210

Area of Science:

• Microbiology
• Natural Product Chemistry
• Pharmacology

Background:

• Streptomyces noursei is a known source of bioactive compounds.
• Fusarium oxysporum f. sp. cubense race four (Foc race four) causes significant crop losses.
• Antitumor activities of microbial natural products are of great interest.

Purpose of the Study:

• To isolate and characterize a novel antibiotic from Streptomyces noursei.
• To evaluate the antifungal activity of the isolated compound against Foc race four.
• To assess the antitumor potential of the compound against human and murine cancer cell lines.

Main Methods:

• Isolation of compound 210-A from Streptomyces noursei Da07210 fermentation broth.
• Structure elucidation using spectral analyses and chemical comparison with cycloheximide.
• Antifungal assays against Foc race four.
• Antitumor assays against SMMC-7721 and S180 cell lines, determining IC(50) values.

Main Results:

• A novel antibiotic, 210-A ((6S,8aS,9S,11S,12aR)-6-hydroxy-9,10-dimethyldecahydrobenzo[d]azecine-2,4,12(3H)-trione), was successfully isolated and its structure confirmed.
• Compound 210-A demonstrated strong activity against Foc race four.
• Significant antitumor activity was observed, with IC(50) values of 0.77 microg/ml against SMMC-7721 cells and 0.74 microg/ml against S180 cells.

Conclusions:

• The novel compound 210-A possesses potent antifungal and antitumor properties.
• This discovery highlights the potential of Streptomyces noursei as a source for new therapeutic agents.
• Further investigation into 210-A's mechanism of action and therapeutic applications is warranted.